

Abnormal Membrane Fluidity as a Cause of Impaired Function of
Chemoattractant Receptors on Neonatal Polymorphonuclear Leukocytes
Modulation of the Receptors by a Membrane Fluidizer

Pediatric Research

24, 442-446

DOI: 10.1203/00006450-198810000-00005

Citation Report

#	ARTICLE	IF	CITATIONS
1	Chemoattractant Receptors of Neonatal Polymorphonuclear Leukocytes: Lack of Modulation of the Receptors by Membrane Modifier. <i>Pediatrics International</i> , 1989, 31, 150-157.	0.5	0
2	Difference in Changes of Membrane Fluidity of Polymorphonuclear Leukocytes Stimulated With Phorbol Myristate Acetate and Formyl-Methionyl-Leucyl-Phenylalanine: Role of Excited Oxygen Species. <i>Journal of Leukocyte Biology</i> , 1990, 47, 105-110.	3.3	26
3	Immunology of the neonate. <i>Current Opinion in Immunology</i> , 1990, 2, 770-777.	5.5	29
4	Effects of Pentoxifylline on Lymphocytes and Polymorphonuclear Leukocytes Membrane Fluidity in Ageing Process. , 1990, , 71-77.		0
5	Decreased Fluidity of Polymorphonuclear Leukocyte Membrane in Streptozocin-Induced Diabetic Rats. <i>Diabetes</i> , 1990, 39, 466-470.	0.6	61
6	Deformability and Volume of Neonatal and Adult Leukocytes. <i>Pediatric Research</i> , 1991, 29, 128-132.	2.3	34
7	Beneficial effect of granulocyte colony-stimulating factor in an infant with <i>Pasteurella multocida</i> brain abscess. <i>European Journal of Pediatrics</i> , 1993, 152, 863-863.	2.7	2
8	<i>Helicobacter pylori</i> positivity. <i>European Journal of Pediatrics</i> , 1993, 152, 863-864.	2.7	0
9	Vascular atherosclerotic disease: Behaviour of the polymorphonuclear leukocyte (PMN) filtration parameters, PMN membrane fluidity and PMN cytosolic Ca ²⁺ content after chemotactic activation. <i>Clinical Hemorheology and Microcirculation</i> , 1996, 16, 523-531.	1.7	2
10	Type II Diabetics with Macrovascular Complications: Polymorphonuclear Leukocyte (PMN) Filtration, PMN Membrane Fluidity and Cytosolic Ca ²⁺ Content after Activation. <i>Hormone and Metabolic Research</i> , 1998, 30, 72-76.	1.5	1
11	Leucocyte Rheology at Baseline and after Activation in Post-Phlebotic Syndrome. <i>Phlebology</i> , 1999, 14, 100-104.	1.2	1
12	Heterogeneity in F-actin polymerization of cord blood polymorphonuclear leukocytes stimulated by N-formyl- methionyl-leucyl-phenylalanine. <i>Pediatrics International</i> , 1999, 41, 37-41.	0.5	12
13	Leukocyte Rheology Before and After Chemotactic Activation in some Venous Diseases. <i>European Journal of Vascular and Endovascular Surgery</i> , 1999, 18, 411-416.	1.5	5
14	Diabetes mellitus: Polymorphonuclear leukocyte (PMN) filtration parameters and PMN membrane fluidity after chemotactic activation. <i>Metabolism: Clinical and Experimental</i> , 1999, 48, 30-33.	3.4	6
15	Acute Ischemic Stroke. <i>Stroke</i> , 2000, 31, 1578-1582.	2.0	8
16	Polymorphonuclear leukocyte membrane fluidity before and after activation in subjects with insulin resistance. <i>Acta Diabetologica</i> , 2000, 37, 9-12.	2.5	11
17	Polymorphonuclear Cytosolic Ca ²⁺ Concentration Before and After Activation in Chronic Renal Failure. <i>Nephron</i> , 2000, 85, 371-372.	1.8	2
18	Polymorphonuclear Integrins, Membrane Fluidity, and Cytosolic Ca ²⁺ Content After Activation in Essential Hypertension. <i>Hypertension</i> , 2000, 36, 813-817.	2.7	11

#	ARTICLE	IF	CITATIONS
19	Deep Venous Thrombosis: Leukocyte Rheology at Baseline and after in vitro Activation. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2000, 30, 168-173.	0.3	5
20	Granulocyte integrins before and after activation in acute ischaemic stroke. Journal of the Neurological Sciences, 2001, 186, 23-26.	0.6	24
21	Polymorphonuclear leucocyte rheology and cytosolic Ca ²⁺ content after activation in chronic renal failure. Nephrology, 2001, 6, 113-117.	1.6	1
22	Polymorphonuclear leukocyte membrane fluidity, at baseline and after in vitro activation, in obesity with or without diabetes mellitus. Acta Diabetologica, 2002, 39, 29-33.	2.5	17
23	Polymorphonuclear leukocyte integrin pattern, at baseline and after activation, in type 2 diabetic subjects with macrovascular complications. Acta Diabetologica, 2003, 40, 14-19.	2.5	11
24	Neutrophil function and disorders of neutrophils in the newborn. , 2005, , 254-279.		0
25	An increase in polymorphonuclear leucocyte chemotaxis accompanied by a change in the membrane fluidity with age during childhood. Clinical and Experimental Immunology, 2008, 81, 156-159.	2.6	13
26	Neutrophil function disorders. , 0, , 231-254.		0
27	Pentoxifylline and CD14 antibody additively inhibit priming of polymorphonuclear leukocytes for enhanced release of superoxide by lipopolysaccharide: possible mechanism of these actions. Infection and Immunity, 1994, 62, 922-927.	2.2	32
28	Fetal and Neonatal Immunology and the Mucosal Immune System. , 2008, , 221-268.		0
30	Signal transduction pathway in human polymorphonuclear leukocytes for chemotaxis induced by a chemotactic factor. Distinct from the pathway for superoxide anion production.. Journal of Immunology, 1994, 152, 5922-5929.	0.8	58
31	Polymorphonuclear phenotypical expression of CD18, at baseline and after in vitro activation, in several clinical disorders: Revision of our case series. Clinical Hemorheology and Microcirculation, 2023, , 1-18.	1.7	2